Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Also known as: Thrombocythemia Myelofibrosis (PET-MF) / Post Essential Thrombocythaemia Myelofibrosis / Post-ET Myelofibrosis / Post ET MF / Post Essential Thrombocythemia Myelofibrosis / Myelofibrosis, Post ET / Post-Essential Thrombocythemia (ET) MF / Post-Essential Thrombocythemia Myelofibrosis / Post Essential Thrombocythemia-myelofibrosis / Post- Essential Thrombocythemia Myelofibrosis / Post-Essential Thrombocythemia MF (Post-ET-MF) / Postessential Thrombocythemia (Post-ET) Myelofibrosis / Post-essential Thrombocythemia Myelofibrosis (PET-MF) / Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) / Post-ET MF / Post Essential Thrombocythaemia Myelofibrosis (PET-MF) / Post-Essential Thrombocythemia Related Myelofibrosis / Myelofibrosis due to and following essential thrombocythemia (disorder) / Myelofibrosis / Myelosis non-leukemic / Agnogenic myeloid metaplasia / Myelofibrosis (disorder) / Myelosis-non-leukaemic / Myelosis non-leukaemic

DrugDrug NameDrug Description
DB08877RuxolitinibA kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment.
DrugDrug NamePhaseStatusCount
DB18454AVID-2001Completed1
DB01262Decitabine1Withdrawn1
DB12396Fresolimumab1Terminated1
DB17561Nisevokitug1Withdrawn1
DB11697Pacritinib1Not Yet Recruiting1
DB06603Panobinostat1Completed1
DB08877Ruxolitinib1Completed1
DB08877Ruxolitinib1Terminated1
DB16322Sabatolimab1Withdrawn1
DB14892Spartalizumab1Withdrawn1
DB11760Talazoparib1Not Yet Recruiting1
DB12638Zelavespib1Terminated2
DB17234Bomedemstat1 / 2Completed1
DB15126IMG-72891 / 2Completed1
DB12784Ilginatinib1 / 2Completed1
DB11763Momelotinib1 / 2Completed2
DB15299Navtemadlin1 / 2Recruiting1
DB06603Panobinostat1 / 2Unknown Status1
DB08910Pomalidomide1 / 2Active Not Recruiting1
DB08877Ruxolitinib1 / 2Active Not Recruiting1
DB08877Ruxolitinib1 / 2Recruiting2
DB06168Canakinumab2Recruiting1
DB12784Ilginatinib2Recruiting1
DB17545Jaktinib2Completed1
DB11763Momelotinib2Active Not Recruiting1
DB11763Momelotinib2Completed3
DB15299Navtemadlin2Recruiting1
DB11697Pacritinib2Completed1
DB09037Pembrolizumab2Completed1
DB08877Ruxolitinib2Completed4
DB08877Ruxolitinib2Terminated1
DB11942Selinexor2Recruiting1
DB14852Zinpentraxin alfa2Completed1
DB15299Navtemadlin2 / 3Recruiting1
DB01406Danazol3Completed1
DB01406Danazol3Recruiting1
DB12500Fedratinib3Completed1
DB01005Hydroxyurea3Recruiting1
DB11763Momelotinib3Completed3
DB11697Pacritinib3Recruiting1
DB11697Pacritinib3Terminated2
DB14867Parsaclisib3Active Not Recruiting2
DB14867Parsaclisib3Not Yet Recruiting1
DB14867Parsaclisib3Recruiting1
DB17129Pelabresib anhydrous3Active Not Recruiting1
DB08877Ruxolitinib3Active Not Recruiting3
DB08877Ruxolitinib3Completed1
DB08877Ruxolitinib3Not Yet Recruiting1
DB08877Ruxolitinib3Recruiting2
DB08877Ruxolitinib4Completed1
DB12500FedratinibNot AvailableRecruiting2
DB08877RuxolitinibNot AvailableAvailable1